Abstract: Disclosed is substantially pure eotaxin DNA sequence and eotaxin polypeptide, and methods of using such DNA and polypeptide to direct chemotaxis of eosinophils. Methods are provided for the treatment diseases and disorders such as inflammation and tumorigenesis.

Abstract: The present invention concerns new compositions and methods for the detection of pathological events. It more specifically concerns methods for the detection in vitro of the presence of a pathology or a pathological event in a subject, comprising taking a sample of blood cells from the subject and determining, in this sample, the presence of blood cells presenting a physiological state characteristic of the pathology. The invention also concerns the tools, kits and compositions for the implementation of such methods, as well as their uses in the field of human and animal health, or in experimental research for example.

Abstract: Disclosed are novel mammalian kinases, p54S6K and p85S6K. Also disclosed are methods for identifying compounds that modulate, or which are modulated by, p54S6K or p85S6K. In addition, the invention discloses methods for diagnosing or treating a cellular proliferative disease.

Abstract: The invention provides methods for treating or identifying subjects having a neurological disease or at risk for a neurological disease by determining the presence of a variant GPIIIa and/or GPIIb allele.

Abstract: There is disclosed novel peptides, fragments or analogues thereof and polynucleotides encoding the same, obtained from streptokinase suitable for use in the amelioration of cell death and methods related thereto.

Abstract: The invention features novel methods and reagents useful for the treatment of excessive or insufficient apoptosis in cells, and, particularly, in germ-line cells. The invention is useful in treating testicular cancers, cancers of germ-line cells, cancers in non-germ-line cell tissues, infertility (e.g., male infertility), and for birth control (e.g., male birth control).

Abstract: Disclosed are diagnostic and prognostic kits for the detection and treatment of proliferative diseases such as ovarian cancer, breast cancer, and lymphoma. Also disclosed are cancer therapeutics utilizing IAP antisense nucleic acids IAP fragments, and antibodies which specifically bind IAP polypeptides.

Abstract: The present invention relates to the length of telomeres and the role of hnRNP A1, UP1 or derivatives thereon. More particularly, the present invention relates to hnRNP A1, UP1 or derivatives thereof to maintain or alter the length of telomeres in cells. The present invention also relates to methods and compositions for increasing or decreasing the proliferative capacity of cells and to delay or precipitate the onset of senescence The invention further relates to hnRNP A1 or UP1 or derivatives thereof as pharmaceutical, therapeutic and diagnostic reagents.

Abstract: Disclosed herein is a method for treating a patient with a neurological disease by determining a patient's BCHE allele status.

Abstract: Provided are worms having deletions in genes associated with Alzheimer's disease and methods for detecting genes and compounds involved in the causation of Alzheimer's disease or useful for the treatment of Alzheimer's disease. A novel method for constructing deletions in the nematode is also provided.

Abstract: The present invention provides a method for the determining the prognosis for a patient diagnosed with a neurological disease. The present invention also provides a method for the identification of human subjects for placement in clinical drug trials of drugs being tested for the treatment of neurological disease and for determining a patient's future disease risk.

Abstract: The present invention is directed to a method for identifying and/or cloning within a biological sample alternatively spliced nucleic acid regions ocurring between two physiological conditions, comprising hybridizing RNA derived from a test condition with cDNA derived from the standard condition and further identifying and/or cloning nucleic acids corresponding to alternative forms of splicing.

Abstract: The invention features substantially purified polypeptide fragments of two specific domains, namely the ART domain and the transmembrane domain, within the BAX protein which, when administered to a cell, increase or decrease apoptosis of the cell. Also disclosed are methods for identifying compounds which, when administered to a cell, increase or decrease apoptosis of the cell. These compounds are identified based on their abilities to interact with specific domains of the BAX protein, or to alter the interaction of the BAX ART domain with the BAX transmembrane domain. In addition, the invention provides methods for diagnosing a patient having, or predisposed to develop, a disease involving altered apoptosis by identifying a mutation in a BAX-encoding gene which results in an amino acid mutation in the BAX ART domain, a BAX transmembrane domain, or that alters the interaction of the BAX ART domain with the BAX transmembrane domain.

Abstract: The invention features methods for stimulating glial cell mitogenesis by contacting the glial cells with p185erbB2 ligand polypeptides, including glial growth factor (GGF), a GGF splice variant comprised of segments E, B, A, C, and C/D or C/D′, a 35 kD polypeptide factor isolated from rat I-EJ transformed fibroblast cells, 75 kD polypeptide factor isolated from the LKBR-3 human breast cells, 44 kD polypeptide factor isolated from the rat I-EJ transformed fibroblast cells, 45 kD polypeptide factor isolated from MDA-MB 231 human breast cells, 7-14 kD polypeptide factor isolated from the ATL-2 human T-cells, 25 kD polypeptide factor isolated from activated mouse peritoneal macrophages, and 25 kD polypeptide factor isolated from bovine kidney.

Abstract: The invention features a general system for the identification of essential genes in organisms. This system is applicable to the discovery of novel target genes for antimicrobial compounds, as well as to the discovery of genes that enhance cell growth or viability.

Abstract: V. cholerae vaccine strains which have a soft agar penetration-defective phenotype and methods for making such strains are described. Also described are methods for identifying new genes involved in V. cholerae motility and the cloning, identification, and sequencing of V. cholerae motB and fliC genes.

Abstract: Disclosed are methods for treating pathophysiological conditions of the mammalian nervous system. The methods involve administering an effective amount of a polypeptide comprising amino acids 51 to 422 of human GGF2.

Abstract: Disclosed are methods for treating pathophysiological conditions of the mammalian nervous system. The methods involve administering pharmaceutically effective amounts of recombinant polypeptides comprising epidermal growth factor-like domains encoded by the GGF/p185erbB2 ligand gene.

Abstract: A method for delivering a biologically active substance including the steps of: (a) combining said biologically active substance with a macromer; (b) forming a mixture of the combination formed in step (a); (c) polymerizing said mixture to form articles; and (d) administering said articles, or a portion thereof, to a mammal, where step (c) takes place in the absence of a polymerizable monovinyl monomer, is disclosed.